Key points are not available for this paper at this time.
May support ATP-capable ICDs for tolerated VT; leaves open need for randomized outcome data.
Antiarrhythmic agents' side effects, proarrhythmic potential, and lack of sustained efficacy contribute to the growing use of implantable cardioverter-defibrillators (ICDs) for patients at risk for out-of-hospital cardiac arrest. Newer ICDs with antitachycardic pacing capability can now be used to treat patients with sustained but hemodynamically tolerated ventricular tachycardia (VT). This German study …
No takes yet. Share an insight, caveat, or question.
GW Dec (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: